Respiratory Clinical Trials Ltd London W1G 8HU UK.
Royal National Throat Nose and Ear Hospital London WC1X 8DA UK.
Immun Inflamm Dis. 2015 Sep 17;3(4):445-54. doi: 10.1002/iid3.86. eCollection 2015 Dec.
Current rhinometric and flow assessments measure nasal patency and are often poorly correlated with rhinitis symptoms. To evaluate magnetic resonance imaging (MRI) as a new method to measure inflammatory changes in nasal and sinus mucosa following nasal allergen challenge. A pilot study (n = 6) determined the optimal technical settings for MRI to measure inflammatory change which were then adopted for the main study. This study was a single blind, placebo-controlled, three-way crossover trial in 14 subjects with seasonal allergic rhinitis. Effects of cetirizine, cetirizine and pseudoephedrine (Cet+PE), or placebo on total nasal symptom scores (TNSS), peak nasal inspiratory flow (PNIF), nasal nitric oxide (nNO), acoustic rhinometry, and MRI end points following nasal intranasal allergen challenge were measured. There were significant changes in all parameters after allergen challenge (P < 0.01), except for nNO. MRI end points were less variable and more consistent than PNIF and acoustic rhinometry in detecting changes after allergen challenge. Total nasal airspace volume was the most sensitive and reproducible MRI measurement, with a mean reduction from -5.37 cm(3) (95%CI -7.35, -3.38; P < 0.001), which was maximal 60 min after allergen challenge. A change of one in TNSS corresponded to a change in MRI volume of -0.57 cm(3). There was an improvement in all parameters (except nNO) in subjects taking Cet+PE compared with placebo, however this did not achieve significance probably because of the small study size (overall analysis P > 0.07; comparison of active versus placebo P > 0.09). MRI provides novel insights into the anatomical inflammatory changes post allergen challenge and provides a new method for assessment of nasal patency and objective measurement of inflammatory responses.
目前的鼻阻力和流量评估可测量鼻腔通畅度,且与鼻炎症状相关性较差。本研究旨在评估磁共振成像(MRI)作为一种测量鼻内变应原激发后鼻腔和鼻窦黏膜炎症变化的新方法。一项纳入 6 例患者的初步研究确定了用于测量炎症变化的 MRI 最佳技术参数,随后将这些参数应用于主要研究中。这是一项纳入 14 例季节性变应性鼻炎患者的单盲、安慰剂对照、三向交叉试验。研究评估了西替利嗪、西替利嗪和伪麻黄碱(Cet+PE)及安慰剂对鼻内变应原激发后总鼻症状评分(TNSS)、最大鼻吸气峰流速(PNIF)、鼻一氧化氮(nNO)、声鼻反射及 MRI 终点的影响。在变应原激发后,所有参数均有显著变化(P<0.01),但 nNO 除外。与 PNIF 和声鼻反射相比,MRI 终点检测变应原激发后变化的变异性更小,更一致。总鼻气道容积是最敏感和可重复的 MRI 测量指标,其平均降低值为-5.37cm3(95%CI-7.35,-3.38;P<0.001),最大降低值出现在变应原激发后 60min。TNSS 变化 1 对应 MRI 容积变化-0.57cm3。与安慰剂组相比,服用 Cet+PE 的患者所有参数(nNO 除外)均有改善,但由于研究规模较小(总体分析 P>0.07;活性药物与安慰剂比较 P>0.09),改善未达统计学意义。MRI 为变应原激发后解剖学炎症变化提供了新的视角,并提供了一种评估鼻腔通畅度和客观测量炎症反应的新方法。